Rapid antibody testing for SARS-CoV-2 vaccine response in pediatric healthcare workers

The COVID-19 pandemic and the responses enacted to limit its devastation have profoundly impacted almost all aspects of society. SARS-CoV-2 vaccinations have the potential to not only reduce morbidity and mortality associated with COVID-19 but also precipitate a return to “normal” life. In phase 2/3 trials, 2 doses of mRNA-1273 demonstrated 94% efficacy in preventing COVID-19, and BNT162b2 has been shown to be 95% effective in preventing COVID-19; both vaccines induce antibodies to the SARS-CoV-2 spike protein.(Baden et al., 2021; Polack, 2021) However, antibody response to vaccines can be highly variable, and it is unknown how or whether the antibody response profile to SARS-CoV-2 vaccines will change over time, and if these changes will be clinically significant.(Zimmermann and Curtis, 2019) To date, several studies have examined the SARS-CoV-2 mRNA vacci ne immune response in relatively small cohorts.(Sahin et al., 2020; Wang et al., 2021; Widge et al., 2021) These studies have all relied on enzyme-linked immunosorbent assay (ELISA), and in many cases, on flow cytometry as well, which is likely not sustainable or practical for fast, inexpensive, and large-scale testing.
Source: International Journal of Infectious Diseases - Category: Infectious Diseases Authors: Source Type: research